1 / 27

Immunity and vaccination to Influenza H1N1 – swine flu

Immunity and vaccination to Influenza H1N1 – swine flu.

janetwhite
Download Presentation

Immunity and vaccination to Influenza H1N1 – swine flu

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Immunity and vaccination to InfluenzaH1N1 – swine flu Mohammad S. KhalifehAssistant Professor, ImmunobiologyDepartment of Veterinary Basic Medical Science Department of Molecular Biology and Genetic Engineering Jordan University of Science and TechnologyTechnical consultantJordan biological Diagnostics Jordan Bio-industrial Center (JOVAC)

  2. KNOWLEDGE IS OUR BEST DEFENSE

  3. The principle immunity to infection

  4. The principle immunity to infection

  5. Mechanisms of adaptive and innate immunity

  6. Influenza Genes • Influenza A viruses have 8 gene segments that encode 10 polypeptides • Segment 1 (2,341 nt): PB2 (RNA transcriptase) • Segment 2 (2,341 nt): PB1 (RNA transcriptase) • Segment 3 (2,233 nt): PA (RNA transcriptase) • Segment 4 (1,778 nt): HA (hemagglutinin) - 16 known subtypes • Segment 5 (1,565 nt): NP (nucleoprotein) • Segment 6 (1,413 nt): NA (neuraminidase) - 9 known subtypes • Segment 7 (1,027 nt): M1, M2 (matrix proteins) • Segment 8 (890 nt): NS1, NS2 (inhibits mRNA splicing and IFN response; nuclear export signal for viral RNPs)

  7. Immunity to Influenza Virus Neutralization Y Y Y Antibody-mediated Opsonization Y Y Y Y Y HA Heterotypic Abs react with proteins of influenza Virus rather than HA and NA

  8. What’s the Problem?!!! Immunopathogenesis and genetics

  9. Type “A” Influenza Viruses Identified by 2 Surface Protein Structures Combinations “H” - Hemagglutinin (1 – 16) Entry into Cell “N” - Neuraminidase ( 1- 9) Exit from Cell 144 Possible combinations

  10. Antigenic Drift “Do I know you? You look vaguely familiar!” Mutation H1N1 H1N1 • Imperfect “manufacturing” of virus • Small changes in H and N • Partial immunity in population • Incomplete protection; still get sick • Need new flu vaccine every year H1N1 This One I Know….. But Yearly epidemics occur H1N1

  11. Antigenic Shift Oh my god…I don’t know you at all !!! This is all what I am seeing H1N1 H1N1 H1N1 H1N1 H1N1 Drives the occurrence of a pandemic Black is my favorite I am Color blind H1N1

  12. Feedback inhibition Vs Heterotypic Abs

  13. Will a current flu vaccine protect me from Swine Flu? Answer: No Vaccines containing the 2008–09 trivalent vaccine virus strains include: • A/Brisbane/59/2007 (H1N1), • A/Brisbane/10/2007 (H3N2), and • B/Florida/4/2006 • All 3 vaccine virus strains were changed for the 2008-2009 season 2007-2008 Vaccine Strains: A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 viruses

  14. Influenza Vaccines • Inactivated (TIV) • intramuscular • trivalent • contains egg protein • Live attenuated vaccine (LAIV) • intranasal • trivalent • contains egg protein

  15. Inactivated Influenza Vaccine Efficacy • Duration of immunity for inactivated influenza vaccine is considered to be 1 year or less • The vaccine is actually effective two weeks after the shot is given. • 70%-90% effective among healthy persons <65 years of age • 30%-40% effective among frail elderly persons • 50%-60% effective in preventing hospitalization • 80% effective in preventing death

  16. A pandemic soon…..Will A Vaccine Be Easy to Produce? • There will be little or no vaccine until 6 - 9 months after the outbreak begins • Production process is slow • 3-6 months until first doses are available • Longer until enough to cover all high-risk groups and general population • For seasonal influenza, viruses are grown in chicken eggs for 7 days to produce high-enough titers for vaccines • Avian influenza viruses kills eggs in 4.5 days • An insufficient titer is generated for vaccines • The world’s annual vaccine capacity is 300 million doses

  17. Challenges • Vaccine Supply (annual uncertainty) • Recommendation vs. prioritization of high-risk groups • Vaccine Distribution (pre-booking) • Vaccine delivery • Vaccine Funding and over-reliance on public health

  18. Live Attenuated Influenza Vaccine (LAIV) • Approved only for healthy persons 2 years through 49 years of age who are not pregnant • healthcare personnel • persons in close contact with high-risk groups • persons who want to reduce their risk of influenza MMWR 2008;57 (RR-7)

  19. Influenza Vaccination • Influenza activity can occur as early as October • Continue to vaccinate throughout influenza season (December-March) • Pregnancy and Influenza Vaccine MMWR 2008;57 (RR-7)

  20. “It would be better to have an immunization program without an epidemic than an epidemic without an immunization program.” (CDC, 1976)

  21. USA guidelines for vaccine priority groups? Tier 1 A Vaccine Producers direct care medical workers B Persons > 65 with compromising conditions C Pregnant women; Household contacts of compromised persons D Public health emergency responders and key public officials. Tier 2 A Healthy 65 and older and children B Emergency response, essential services Tier 3 Key government and society leaders Tier 4 Healthy Persons

  22. The only thing more difficult than planning would be explaining why you did not do it! -- Marja Esveld Healthcare Inspectorate, The Netherlands

  23. Cold vs. “Flu” (influenza)

  24. WHO Phases of a Pandemic Current level

  25. Lab Testing • Preferred specimen: nasopharyngeal/nasal swab, wash, aspirate • Rapid influenza tests • Results within 30 minutes • May determine type (A vs. B) • High false negative results (30%) • Viral culture • Results in 3-10 days • Determine specific subtype or strain • reference standard of diagnosis • Not necessary to test all patients • May not affect clinical decision-making • Expensive • Labor intensive • Cohort hospitalized patients • Outbreaks

More Related